Home > Healthcare & Medical Devices > Cancer Biological Therapy Market

Cancer Biological Therapy Market Size By Product (Monoclonal Antibodies {Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies}, Vaccines {Preventive Vaccines, Therapeutic Vaccines}, Cancer Growth Blockers {Tyrosine Kinase Inhibitors, Proteasome Inhibitors, mTOR Inhibitors}, Blood Cell Growth Factors {Lenograstim, Filgrastim}, Cytokine {Interferon, Interleukin}), By Route of Administration (Oral, Injectable), COVID-19 Impact Analysis, Regional Outlook, Product Potential, Competitive Market Share & Forecast, 2021 – 2027

  • Report ID: GMI676
  • Published Date: Jul 2021
  • Report Format: PDF

Industry Overview

Cancer Biological Therapy Market size is estimated to grow at 7.8% CAGR between 2021 and 2027. Rising awareness regarding cancer and cancer treatments among the population will drive the market growth. Increasing pervasiveness of lung cancer will augment the demand for cancer biological therapy.

Cancer Biological Therapy Market Overview

Get more details on this report - Request Free Sample PDF

The spread of the COVID-19 pandemic across the globe has impacted the cancer biological therapy market negatively by disrupting the spectrum of cancer care in 2020. The industry has witnessed a drop in sales of cancer biological drugs during pandemic. Furthermore, the COVID-19 pandemic overburdened the healthcare services, therefore many countries suspended cancer diagnosis or screening and delayed cancer related surgeries.

Increasing prevalence of cancer will propel the demand for cancer biological therapy

The growing prevalence of cancer will impel the demand for cancer biological therapy industry. According to the World Health Organization, cancer is one of the leading causes of death worldwide with more than 10 million deaths in 2020 alone. Additionally, there has been a rise in the global cancer burden of 19.3 million cases. Such high disease burden across the globe is expected to boost the demand for therapy, thereby driving the industry growth. Furthermore, growing interaction with external carcinogens along with the increase in the consumption of alcohol and tobacco will surge the risk of developing cancer, fueling the overall market demand.

High cost of cancer biotherapy in developing countries will restrict the industry expansion

The high cost of cancer biological therapy may slow down the cancer biological therapy market revenue in the coming years. For instance, the average treatment cost for lung cancer is around $282,000. Additionally, prices for cancer biological therapy drugs are constantly increasing every year owing to huge investments on R&D of novel drugs. Also, the medical insurance does not cover the treatment completely because of which people struggle with high out-of-pocket medical costs. Thus, high cost has been negatively influencing the market and will continue to restrain the industry progression in the future.

Growing adoption of monoclonal antibodies for cancer treatment will foster the industry demand

Cancer Biological Therapy Market Size

Get more details on this report - Request Free Sample PDF

The monoclonal antibodies (MAB) segment of cancer biological therapy market accounted for USD 33.5 billion in 2020. The increasing burden of cancer worldwide will accelerate the demand for cancer biological therapy and fuel the industry revenue. The monoclonal antibody-based treatment is considered as the main component in the treatment of cancer alongside chemotherapy, radiation, and surgery. As antibodies are very specific, they target the cancer cells directly without harming the healthy cells and induce a long anti-tumor immune response. Also, regulatory approval of antibodies-based cancer therapies will surge the industry demand in the coming years.

Rising use of injectables for new cancer treatments will spur the market statistics

The cancer biological therapy market from injectable segment surpassed USD 38 billion in 2020 and is set to register a significant CAGR through 2027 led by the increasing usage of antibodies-based cancer treatment. Moreover, a number of deaths owing to lung cancer is rising every year. According to WHO, in 2020 more than 1.80 million deaths occurred globally because of lung cancer. To reduce the burden of cancer, discovery of new treatments and drugs is very critical. In addition, market is highly research-driven, the industry is dependable on the discovery of new drugs or molecules that can generate an immune response against residing cancer. This immune response is achieved the maximum with injectables.

North America regional dominated the overall market share

North America cancer biological therapy market is poised to showcase 7.6% CAGR up to 2027. The rising incidence of cancer is attributed to the acceptance of a sedentary lifestyle along with unhealthy dietary habits, alcohol, and drug abuse. In the U.S. more than 1.8 million cases of cancer was diagnosed in 2020 and around 606,520 people died due to cancer. The most common cancer found in U.S. population is breast cancer, lung cancer, and prostate cancer.

Global Cancer Biological Therapy Market  

Get more details on this report - Request Free Sample PDF

Growth strategies of market players are focused on increasing the customer base

A few key companies operating in the cancer biological therapy market are AbbVie, Merck, AstraZeneca, GlaxoSmithKline, ELI Lilly and Company, Otsuka, Pfizer, Hoffmann-La Roche, Novartis and Takeda Pharmaceuticals among others. These market leaders are focusing on numerous strategies such as mergers, acquisitions, partnerships, new product launches, and collaborations to increase their revenue share.

Recent industry developments:

  • In April 2020, Roche launched atezolizumab (cancer immunotherapy drug) in India. The atezolizumab is used for the treatment of metastatic triple-negative breast cancer. This strategy boosted the company’s product portfolio and generated more customers for cancer biological therapy.
  • In December 2020, Bayer and Atara Biotherapeutics announced their collaboration for R&D, worldwide license agreement, and manufacturing for mesothelin-targeted CAR T-cell therapy for the treatment of various solid tumors. This strategy is set to strengthen the market position and oncology product pipeline of the company.

The cancer biological therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

By Product

  • Monoclonal antibodies (MAB)
    • Naked MAB
    • Conjugated MAB
    • Bispecific MAB
  • Vaccines
    • Preventive vaccines
    • Therapeutic vaccines
  • Cancer growth blockers
    • Tyrosine kinase inhibitors (TKI)
    • Proteasome inhibitors (PI)
    • mTOR inhibitors
  • Blood cell growth factors (BCGF)
    • Lenograstim
    • Filgrastim
  • Cytokines
    • Interferons
    • Interleukins

By Route of administration

  • Oral
  • Injectable

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Argentina
    • Mexico
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE


Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

The market size exceeded USD 97.8 billion in 2020 and will expand at a CAGR of 7.8% from 2021 to 2027.

Monoclonal antibodies accounted for a revenue of USD 33.5 billion in 2020 and will depict commendable growth owing to the escalating burden of cancer at the global level.

Injectables recorded a valuation of USD 38 billion in 2020 and will register substantial growth due to the rising adoption of antibodies-based cancer treatment.

North America market value will register a growth rate of 7.6% through 2027 due to the increasing incidence of cancer owing to the adoption of a sedentary lifestyle.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2020
  • Companies covered: 19
  • Tables & Figures: 376
  • Countries covered: 17
  • Pages: 150

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount